Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PANRETIN vs AKRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
FDA-approved: Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma,Off-label: Treatment of chronic hand eczema (oral formulation, not available in US)
Allergic rhinitis,Nasal congestion
Apply 0.1% gel topically to lesions twice daily.
Adults: 100 mg orally twice daily.
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes.
Not available; components may be metabolized via hepatic CYP enzymes.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
>99% bound to plasma proteins, primarily albumin and lipoproteins.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Not applicable for topical administration; systemic absorption is minimal with no established Vd.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Systemic bioavailability after topical application is <1% of applied dose.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
No dose adjustment required for renal impairment.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment recommended for hepatic impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Not indicated for pediatric patients below 18 years of age.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
No specific dose adjustment; use with caution due to potential for increased skin sensitivity.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
None
Teratogenicity: Avoid use during pregnancy; effective contraception required,Photosensitivity: Avoid excessive sun exposure,Local skin reactions: erythema, edema, peeling at application site,Hyperlipidemia: Monitor lipids in prolonged use,Pancreatitis: Risk in patients with hypertriglyceridemia,Hepatotoxicity: Monitor liver function tests,Pseudotumor cerebri: Discontinue if signs of intracranial hypertension
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Hypersensitivity to alitretinoin or any component of the formulation,Pregnancy (topical: use only if no safer alternative; oral: absolutely contraindicated)
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
No known food interactions. Avoid concurrent use of other topical products on the same area.
No known food interactions with topical naftifine. No dietary restrictions required.
PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
No data on excretion in human milk. Retinoids are known to be excreted in animal milk. Because of potential for serious adverse reactions in nursing infants (teratogenicity, retinoid toxicity), breastfeeding is contraindicated during therapy and for at least 1 month after last dose.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
Contraindicated in pregnancy; no dose adjustments applicable. Ensure patient is not pregnant before initiating therapy.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin.,Wash hands thoroughly before and after application.,Do not cover with bandages or dressings unless instructed.,Expected side effects include redness, swelling, and pain at application site.,Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PANRETIN vs AKRINOL, answered by our medical review team.
PANRETIN is a Topical Retinoid that works by Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.. AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PANRETIN and AKRINOL depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PANRETIN is: Apply 0.1% gel topically to lesions twice daily.. The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PANRETIN and AKRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PANRETIN is classified as Category C. PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnor. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.